AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03821259 — intervention group
Intervention type: OTHER
Intervention: Psychological measures
Description: Participants will be asked to provide basic demographic information and to complete five measures, screening for cognitive impermanent and measuring PTSD symptoms, lifetime trauma exposure, emotion regulation and group identification.
Study NCT00596687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Insulin glargine once daily SQ
Study NCT00596687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
Study NCT00596687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: scheduled glulisine given SQ at mealtime TID; none given if patient NPO
Study NCT01365078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echium oil (SDA-rich oil)
Description: The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
Study NCT01365078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: high-oleic acid sunflower oil (HOSO) (low in SDA)
Description: The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
Study NCT01999699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV
Study NCT00627965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: 50mg tds
Study NCT00627965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tds
Study NCT03030560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
Study NCT03030560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
Study NCT00887848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lokomat training
Description: 15 sessions of Lokomat training within 5 weeks (3 trainings/week)
Study NCT00887848 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lokomat training
Description: 15 sessions of Lokomat training within 5 weeks (3 trainings/week)
Study NCT05832853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wu Qin Xi exercise
Description: The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
Study NCT05832853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wu Qin Xi, resistance training and endurance training
Description: During the first 8 weeks, the training consists of learning and consolidating the movements of the Wu Qin Xi. In the second 16 weeks, participants perform a full set of movement exercises. Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and two sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 15 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
Study NCT05832853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training and endurance training
Description: Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and three sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 30 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
Study NCT01497912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg once daily for 8 weeks
Study NCT01497912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily for 8 weeks
Study NCT03014544 — intervention group
Intervention type: DEVICE
Intervention: Computer- administered test battery
Description: Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
Study NCT03014544 — intervention group
Intervention type: DEVICE
Intervention: Examiner- administered test battery
Description: Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
Study NCT04388917 — intervention group
Intervention type: PROCEDURE
Intervention: Patial nephrectomy
Description: Partial nephrectomy assisted with robot to remove kidney cancer
Study NCT01748578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-1
Description: EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
Study NCT01748578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-1 Placebo
Study NCT04320810 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: It's only observational study. No interventions.
Study NCT03190317 — intervention group
Intervention type: OTHER
Intervention: HIV-infected Veterans who use MHV
Description: The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
Study NCT03190317 — intervention group
Intervention type: OTHER
Intervention: HIV-infected Veterans who do not use MHV
Description: The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
Study NCT03190317 — intervention group
Intervention type: OTHER
Intervention: Providers and staff of HIV-infected veteran
Description: The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
Study NCT01618266 — intervention group
Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
Study NCT04243174 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SMS Messaging
Description: Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
Study NCT03449082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High concentration of Allo-ASC
Description: 10 million cells of Allo-ASC 0.5cc
Study NCT03449082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low concentration of Allo-ASC
Description: 1 million cells of Allo-ASC 0.5cc
Study NCT03449082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: Fibrin glue 0.5cc
Study NCT03449082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibrin glue
Description: Fibrin glue 0.5cc
Study NCT03449082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 0.5cc
Study NCT00419926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (Myfortic)
Description: 1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
Study NCT00419926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (Myfortic)
Description: 1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
Study NCT00419926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Neoral)
Description: cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
Study NCT00419926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (Neoral)
Description: cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
Study NCT03531047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Customised CXL
Description: As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
Study NCT04320628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnaSept®
Description: AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
Study NCT04320628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS
Study NCT03464812 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DSMES
Description: It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
Study NCT02948569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-V Bioscience-2640
Description: Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
Study NCT01204801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Microwave Thermotherapy
Description: Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
Study NCT01204801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (control)
Description: Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
Study NCT02368808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abangane Support Group
Description: The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
Study NCT01040260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Smoking cessation counseling
Study NCT01040260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Use of tangible rewards for abstinence from smoking
Study NCT01040260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Nicotine patches
Study NCT00520780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject ® (Ferric carboxymaltose)
Description: Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
Study NCT00520780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9%)
Description: During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
Study NCT01189279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation A
Description: bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
Study NCT01189279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation B
Description: bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
Study NCT01189279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation C
Description: bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
Study NCT04557072 — intervention group
Intervention type: DRUG
Intervention: Selective alpha-1-antagonist
Description: Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
Study NCT04557072 — intervention group
Intervention type: DRUG
Intervention: Non-selective alpha-1-antagonist
Description: Patients treated with non-selective alpha-blockade (phenoxybenzamine)
Study NCT02120508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: To test the efficacy of this specific setting.
Study NCT02120508 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: To test the efficacy of this specific setting.
Study NCT04230044 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets.
Study NCT03280121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsophyX ZR transoral device
Description: TIF
Study NCT02396745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
Description: TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA).
Study NCT03765866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastometry guided transfusion
Description: Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
Study NCT01371214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLIÉ (Preventing Loss of Independence through Exercise)
Description: Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
Study NCT01371214 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLIÉ (Preventing Loss of Independence through Exercise)
Description: Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
Study NCT00419926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
Study NCT00419926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
Study NCT04122274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCAA education sheet
Description: A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
Study NCT04122274 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: NCAA education sheet
Description: A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
Study NCT04122274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Intervention
Description: An approximately 7-minute video that includes information about basic sports nutrition facts.
Study NCT04122274 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Decision-based interactive concussive education platform
Description: A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
Study NCT02506790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Study NCT01631630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
Study NCT01631630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive tablet design to look exactly like pioglitazone
Study NCT02923843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
Study NCT01146496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultraviolet light-resistant plastic in-ground pesticide storage container
Description: In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
Study NCT03764332 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stabilometry
Description: To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
Study NCT01531166 — intervention group
Intervention type: DRUG
Intervention: pegylated Interferon-alpha 2a
Description: Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
Study NCT04052464 — intervention group
Intervention type: OTHER
Intervention: endometrium biopsy
Description: All patients will have endometrium biopsy.
Study NCT04052464 — intervention group
Intervention type: OTHER
Intervention: endometrium lavage
Description: In some selected cases biopsy is preceded by endometrium lavage.
Study NCT04052464 — intervention group
Intervention type: OTHER
Intervention: repeated endometrium lavage
Description: Endometrium lavage is repeated during the same cycle.